PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024: Cantor Fitzgerald Global Healthcare Conference About Cantor Fitzgerald Global Healthcare Conference Nanox’s Chief Executive Officer and Acting Chairman, Erez Meltzer, and Chief Financial Officer, Ran Daniel, will engage in a fire ...

The price trend for Nano-X Imaging Ltd. (NNOX) has been bearish lately and the stock has lost 19.7% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only fa ...

HealthCCSng V2.0 introduces additional ‘zero calcium’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output Marks second FDA 510(k) clearance of HealthCCSng product PETACH TIKVA, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, received 5 ...

财务数据和关键指标变化 - 公司在第二季度的GAAP净亏损为1360万美元,较上年同期的1740万美元有所下降 [35] - 公司在第二季度的收入为270万美元,毛亏损为290万美元,而上年同期收入为260万美元,毛亏损为117万美元 [36] - 公司在第二季度的非GAAP毛亏损为90万美元,而上年同期为非GAAP毛利900万美元,毛利率从34%下降至9% [36] 各条业务线数据和关键指标变化 - 远程放射诊断服务业务在报告期和上年同期的收入均为250万美元,毛利为40万美元,毛利率约为15% [37] - 公司在报告期内通过销售AI解决方案实现收入11.3万美元,上年同期为5.3万美元 [38] - 公司在报告期内通过销售和部署成像系统实现收入6.8万美元,毛亏损为130万美元 [39] 各个市场数据和关键指标变化 - 在美国,公司已在7个州部署了几十台Nanox.ARC系统,正在等待其他2个州的批准 [15][51] - 公司已在以色列部署2台Nanox.ARC系统,并计划在未来几个月内部署更多 [18] - 公司正在等待进口许可证,准备在墨西哥部署首台Nanox.ARC系统 [18] 公司战略和发展方向及行业竞争 - 公司正在加快执行商业基础设施和未来战略合作,目标是为医疗机构提供具有成本优势的Nanox.ARC成像解决方案 [44][45] - 公司正在开发新的Nanox.ARC X系统,计划与现有系统一起推向市场,以满足客户和临床合作伙伴的需求 [30][31] - 公司正在与美国政府实体合作,开发新型管芯,并与Varex合作集成到新的Nanox.ARC系统中 [32][33] 管理层对经营环境和未来前景的评论 - 公司在2024年取得了强劲的商业进展,同时通过临床努力提升了产品价值 [10] - 公司正在加快在美国和全球的部署,同时也在扩大Nanox.AI等其他解决方案的应用 [10] - 公司对未来发展充满信心,将继续改进产品并满足市场需求 [29][44] 其他重要信息 - 公司已获得FDA对HealthCCSng 2.0版本的新的510k认证,可以更精确地评估冠状动脉钙化 [48] - 公司已提交新的510k申请,旨在扩大Nanox.ARC系统的适用范围,包括胸部成像 [12][13] - 公司已完成ISO 13485认证并通过MDR审核,正在与主管部门就欧洲CE认证进行最后阶段的沟通 [14] 问答环节重要的提问和回答 问题1 **Jeffrey Cohen 提问** 询问公司在美国的订单和部署情况 [50] **Erez Meltzer 回答** 公司在美国已有几十台系统处于各个阶段的部署,未来几个月将继续增加 [51] 问题2 **Scott Henry 提问** 询问公司提交的新的510k申请的审批时间预期 [60] **Erez Meltzer 回答** 公司无法准确预测审批时间,但预计获批后将大幅提升Nanox.ARC在美国的应用 [61][62] 问题3 **Ross Osborn 提问** 询问公司在欧洲的商业化计划 [79] **Erez Meltzer 回答** 公司将利用分销商在欧洲等地区推广Nanox.ARC,主要面向中大型医疗中心 [80][81][82]

文章核心观点 - 公司在第二季度取得了商业上的进展,推进了Nanox.ARC在美国市场的部署 [3][4][5] - 公司提交了新的510k申请,扩大了Nanox.ARC的适用范围,包括一般用途和胸部 [2][4] - 公司的Nanox.AI心脏解决方案HealthCCSng V2.0获得FDA 510K认证,增加了"零钙"冠状动脉钙化评估分类 [2][4] 财务表现 - 第二季度收入为2.7百万美元,同比增长 [7] - 毛亏损为2.9百万美元,非GAAP毛亏损为0.2百万美元 [8][16] - 研发费用和管理费用同比下降 [13][14] - 非GAAP净亏损为8.4百万美元,同比下降 [15] - 截至6月30日,现金及等价物为64.2百万美元 [18] 业务进展 - 在美国部署Nanox.ARC系统,已安装在7个州,销售渠道良好 [4] - 与3家连锁医疗影像服务提供商在美国安装了初期Nanox.ARC系统 [4] - 正在开发新一代Nanox.ARC X系统,将在下一次投资者活动中推出 [4]

In a study conducted by Brigham & Women's Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards' Winner In a study conducted by Jefferson Einstein Hospital, Nanox.AI Cardiac Solution Flags CAD High-Risk Patients, Drives Significant Revenue Additional data presented by Corewell Health, Massachusetts General Hospital and Rabin Medical Center PETACH TIKVA, Israel, July 25, 2024 (GLOBE NEWS ...

文章核心观点 - Nvidia是人工智能领域的主导供应商,其GPU产品需求强劲 [2] - Nvidia还投资了几家人工智能公司,这些公司的股价有望大涨73%至89% [3] Nano-X Imaging - Nano-X Imaging是一家医疗技术公司,开发了更加经济实惠的医疗成像技术 [6] - 该公司还有一家子公司Nanox.AI,使用人工智能诊断未被发现的慢性疾病 [6] - 分析师普遍看好Nano-X Imaging的股价,预计未来12个月内上涨89% [4][5] Recursion Pharmaceuticals - Recursion Pharmaceuticals将自己定位为"TechBio"公司,而非传统生物科技公司,强调利用技术进行药物发现和开发 [9] - 该公司拥有世界上最快的由制药公司自主拥有和运营的超级计算机BioHive-2,使用人工智能模型发现新药 [9] - 分析师预计Recursion Pharmaceuticals的股价未来12个月内将上涨73% [8] Soundhound AI - Soundhound AI是一家纯粹的人工智能公司,是语音人工智能系统的领导者,为汽车制造商、餐厅、智能电视制造商等提供服务 [12] - Soundhound AI 2024年第一季度收入同比增长73% [15] - 分析师预计Soundhound AI的股价未来12个月内将上涨79% [11]

For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Nano-X Imaging Ltd. (NNOX) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Nano-X Imaging Ltd. is a member of our Business Services group, which includes 315 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order ...

PETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C. The studies are being presented by esteemed institutions Brigham & Women's H ...

PETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C. The studies are being presented by esteemed institutions Brigham & Women's H ...